Not available

Diarrhoea, Giddiness, hypotension. Nausea, vomiting, disturbance in color vision hypotension,( after rapid IV inj ) thromboembolic events

Severe renal failure, active intravascular clotting, thromboembolitic disease, color vision disorders, subarcachoid bleeding

Special Precautions:

Mild to moderate renal impairment, irregular menstrual bleeding, previous history of thromboembolic disease, hematuria, Monitor closely in disseminated intravascular coagulation. Monitor closely LFT and eye exam regularly during long term use. Discontinue disturbance in color vision occurs Avoid IV inj rate > 1 ml.minute due to risk of hypotension Pregnancy Lactation

Date of Approval       2002

Indications:

Hemorrhage

Dosage:

Give 25mg/kg orally, 3 to 4 times daily beginning 1 day before surgery. Parentral: 10mg/kg bid or tid for patients unable to take oral medication.

Antifibrinolytic agents- include amionocaproic acid , tranexamic acid- Refer aminocaproicacid 

Pharmacology:

Tranexamic acid is a competitive inhibitor of plasminogen activation, and at a much higher concentration, a noncompetitive inhibitor of plasmin. It has action similar to aminocaproic acid.

Pharmacokinetics:

Absorption of tranexamic acid after oral use is about 30% to 50%, bioavailability is not affected by food. The peak plasma level 3 hour after 1g orally is 8mg/l. The biological half-life in the joint fluid is about 3 hours.

Pregnancy: Use only if clearly needed.

Lactation: Excercise caution when administering to nuring women.